Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 2;9(1):153.
doi: 10.1038/s41531-023-00585-y.

Overview on wearable sensors for the management of Parkinson's disease

Affiliations
Review

Overview on wearable sensors for the management of Parkinson's disease

Caroline Moreau et al. NPJ Parkinsons Dis. .

Abstract

Parkinson's disease (PD) is affecting about 1.2 million patients in Europe with a prevalence that is expected to have an exponential increment, in the next decades. This epidemiological evolution will be challenged by the low number of neurologists able to deliver expert care for PD. As PD is better recognized, there is an increasing demand from patients for rigorous control of their symptoms and for therapeutic education. In addition, the highly variable nature of symtoms between patients and the fluctuations within the same patient requires innovative tools to help doctors and patients monitor the disease in their usual living environment and adapt treatment in a more relevant way. Nowadays, there are various body-worn sensors (BWS) proposed to monitor parkinsonian clinical features, such as motor fluctuations, dyskinesia, tremor, bradykinesia, freezing of gait (FoG) or gait disturbances. BWS have been used as add-on tool for patients' management or research purpose. Here, we propose a practical anthology, summarizing the characteristics of the most used BWS for PD patients in Europe, focusing on their role as tools to improve treatment management. Consideration regarding the use of technology to monitor non-motor features is also included. BWS obviously offer new opportunities for improving management strategy in PD but their precise scope of use in daily routine care should be clarified.

PubMed Disclaimer

Conflict of interest statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors declare no competing interests, with the exception of C.M., who is the chief medical officer for FeetME and Inbrain Pharma.

Figures

Fig. 1
Fig. 1. Body worn sensors for Parkinson’s disease management.
Authors have obtained consent to publication of the image from PD Neurotechnology Ltd, Global Kinetics, Sense4Care, McRoberts, GreatLakes Neurotechnologies, APDM Wearable Technologies and FeetMe.

References

    1. Moisan F, K. S., Moutengou E., Boussac-Zerebska M., Carcaillon-Bentata L., & Elbaz A. Fréquence de la Maladie de Parkinson en France. Données Nationales et Régionales 2010-2015. (2019).
    1. Wanneveich M, Moisan F, Jacqmin-Gadda H, Elbaz A, Joly P. Projections of prevalence, lifetime risk, and life expectancy of Parkinson’s disease (2010-2030) in France. Mov. Disord. 2018;33:1449–1455. doi: 10.1002/mds.27447. - DOI - PubMed
    1. Carriere N, et al. Descriptive study of the parkinsonian population in the north of France: epidemiological analysis and healthcare consumption. Rev. Neurol. 2017;173:396–405. doi: 10.1016/j.neurol.2017.03.036. - DOI - PubMed
    1. Reichmann, H., Klingelhoefer, L. & Bendig, J. The use of wearables for the diagnosis and treatment of Parkinson’s disease. J. Neural. Transm. 10.1007/s00702-022-02575-5 (2023). - PMC - PubMed
    1. Warren Olanow C, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov. Disord. 2013;28:1064–1071. doi: 10.1002/mds.25364. - DOI - PubMed